How to work in partnership with the LPP
Upcoming SlideShare
Loading in...5
×
 

How to work in partnership with the LPP

on

  • 420 views

 

Statistics

Views

Total Views
420
Views on SlideShare
198
Embed Views
222

Actions

Likes
0
Downloads
3
Comments
0

4 Embeds 222

http://www.pmsociety.org.uk 165
http://pmsociety.org.uk 54
http://87.248.112.8 2
http://sym2pmwanda.pmsociety.org.uk 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

How to work in partnership with the LPP How to work in partnership with the LPP Presentation Transcript

  • LPP: How to work inpartnership with the LPPJasbinder Khambh, Pharmacy & Medicines Use & Procurement Lead for PrimaryCare | NHS London Procurement Partnership
  • Managing Medicinesin the NHS – LondonPerspectiveJas KhambhPharmacy & Medicines Use & ProcurementOperational Lead & Lead for Primary Care, LPPTim RootStrategic Pharmaceutical Lead, LPP
  • Today’s Objectives•An overview of how medicines are managed inthe NHS (in London)•An overview of the Medicines Use andProcurement QIPP Workstreams in London
  • The New Landscape•Abolition of PCTs & SHAs•Commissioning power shared between NHSEngland (was NHS Commissioning Board) andGPs•So we have:NHS England – direct commissioning &oversight of CCG commissioningClinical commissioning groups – directcommissioningLocal authorities: social services, publichealth services
  • Managing medicines•National guidance and priorities• NHS Constitution• Innovation health and wealth• NICE – good practice guidance on developingand updating local formularies (Dec 2012)•Local guidance & priorities• Formularies•Variance across the country• Decision making groups: stakeholderengagement, processes• Criteria for decision making• Decision outputs
  • Managing the introduction of new medicines –factors considered•Patient safety•Budget impact•Strength of evidence• Place in therapy• Clinical effectiveness• Cost effectiveness•Equity of access•Stakeholder views
  • On the horizon?• Continuing fiscal constraint• Value-based pricing• NHS England contracting for medicines• Greater consistency about commissioning for high-costPbRX medicines
  • Pan-London Management of Medicines throughthe QIPP agenda•LPP•Built on• 30 years medicines management & medicinesprocurement expertise in acute trusts• Pharmacy & Medicines Management work of the LPP.•There are 3 workstreams:Primary CareAcute & MH Trusts (Secondary Care)Cross-sector
  • 9Pharmacy & Medicines Use & ProcurementGovernance Model for LondonLPP & Medicines Use andProcurement ProductivitySteering GroupAd hoc projects /Task & finish groupLPP PharmacyMedicinesManagement Group/Secondary careQIPP Sub-GroupLPP Steering BoardCommercial Board /Productivity PLG atNHSLNHS England Trusts and PCTsQIPPguidanceMonthlyQIPPreportingSubscriptionsMonthlyQIPPworkstreamreportingHigh levelcommentonworkstreamMonthly projectreporting againstplanMonthly projectreporting againstplanPrimary Care QIPPSub-GroupProjectinitiation,milestoneand resultsreportingCombined and co-ordinated LPP andproductivityreporting
  • NHS London Procurement Partnership – Pharmacy, Medicines Use& Procurement WorkstreamKey Objectives and Priorities for 2013 - 201532 CCGSand3 CSUsQIPP Promotes & supports across the NHS in London: Evidence based choice of medicines Safe , cost-effective use of medicines (£) Reduced medicines waste (£) Recommendations and advice to prescribers and medicines management teams Specialist analytics & informatics support, key performance indicators anddashboards Management of primary care rebate schemes (£)Medicines Optimisation Safe use of medicines and improved quality of patientcare:optimised patient experience & treatment outcomes Medicines optimisation as part of routine practiceContinuity & quality of care involving medicines use,across theprimary/secondary/tertiary/social care interfaces Specialist pharmaceutical support for optimisation ofprescribing for complex therapeutic areas such as mentalhealth, cancer chemotherapy , nutrition and dietetics (£)Collaboration and sharing of best practice London-wide stakeholder engagement and working groups Pan-London solutions Do once and share : efficient use of limited resources (£) Facilitated access to key advice & information at www.lpp.nhs.uk(£) Training and education Collaborative working with external stakeholders e.g.pharmaceutical industryProcurement of the most cost-effectivemedicines for acute & mental health trusts Expert knowledge and specialist expertise from medicinesprocurement specialists Pan-London contracts to secure best value-for-money (£) Strategic clinical medicines procurement (£) Support for management of expenditure on:high cost PBR excluded drugs (£)supply of medicine through Homecare (£)Patient Access Schemes (£)Acute andMentalHealthTrustsNote: All of these objectives aim toimprove productivity and quality ofpatient care. Objectives marked (£)can provide significant financialsavings to the local health economyin London. These savings may bequantified in terms of return ininvestment and against keyperformance indicators.
  • Primary Care QIPP Workstream• Engagement with CCGs/CSUs• Collaborative approach• Primary Care QIPP sub-group• Priority setting• Medicines Information & Specialist Pharmacy Servicessupport• Data collection, analysis & reporting• Dashboards• Rebate schemes
  • 2013/14 priorities• Engagement with new stakeholder groups• CCGs, CSUs, NHS England• Quality & Safety• Cross-sector• Extend & Refine data presentation• Split dashboards• Acute & MH Trusts• Define® benchmarking tool• Primary Care• Financial• Quality & safety• Mental Health• Nutrition
  • Primary Care Clinical Priorities for2012/13Cardiovascular•Renin-angiotensin system drugs•Statins•EzetimibeEndocrine•Diabetes•OsteoporosisCentral Nervous System•Prescribing in mental health•Low dose antipsychotics•Hypnotics•Venlafaxine•Pain controlOther Therapeutic areas•Glucosamine•Prednisolone•Wound care•Specials•Vitamin D•Oral nutritional supplements•Antimicrobials
  • Tools and resourceswww.lpp.nhs.uk• Dashboards• KPIs and Red Amber Green ratings• CCG and CSU level (not practice level)• Benchmarked data including savings / lostopportunity• Key messages bulletins with MI• Supporting information for procurement• Newsletters for chief executives• Working groups• Specialist pharmacist advice & tools to supportimplementation• Events
  • LPP website
  • LPP website
  • Trend graphs for PCTs/Clusters
  • Dashboard BenchmarkingGraphs
  • Secondary care dashboard
  • Final points• Engagement with the clinical commissioning groups• Understand new stakeholders & their priorities•Support CCGs and Trusts to improve performance• Support local QIPP plans• Share good practice• Pan-London approach• Collaborative working between primary & secondarycare• Enhance Dashboards• Collaborative working with community pharmacists• Collaborative working with the pharmaceutical industry
  • www.lpp.nhs.ukJasbinder.khambh@lpp.nhs.ukTim.root@chelwest.nhs.uk